AMRN250117P5000
- 3.20
- 0.000.00%
Amarin Newsroom
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading
Amarin Corporation Announces National Reimbursement Approval for VAZKEPA in Italy to Reduce Cardiovascular Risk in High-Risk Patients
Executive Reshuffles: JPM, QCOM, DVN and LTC
Press Release: Amarin Appoints Peter Fishman Chief Financial Officer
Express News | Amarin Appoints Peter Fishman Chief Financial Officer
Express News | Amarin Corp - Nasdaq Granted 180 Days to Regain Nasdaq Compliance
After Plunging -19.13% in 4 Weeks, Here's Why the Trend Might Reverse for Amarin (AMRN)
Top 3 Health Care Stocks You'll Regret Missing In Q4
Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA), Bolt Biotherapeutics (BOLT) and Amarin (AMRN)
US Manufacturing Index Rises To 43, Highest Since 2020
Amarin Corporation Announces That Investigators Will Present An Additional Subgroup Analysis From The REDUCE-IT Outcomes Trial In Patients With And Without Coronary Artery Disease History And Mechanistic Data On Eicosapentaenoic Acid At The American...
European Equities Traded in the US as American Depositary Receipts Fall in Thursday Trading
Amarin Corporation Plc (AMRN) Q3 2024 Earnings Call Transcript
Amarin: Q3 Earnings Snapshot
Earnings Flash (AMRN) AMARIN CORPORATION Reports Q3 Revenue $42.3M
Amarin | 10-Q: Q3 2024 Earnings Report
Amarin | 8-K: Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update
Amarin Non-GAAP EPS of -$0.05 Beats by $0.01, Revenue of $42.3M Misses by $2.21M
Amarin Corp Q3 2024 GAAP EPS $(0.06) Misses $(0.05) Estimate, Sales $42.300M Miss $44.510M Estimate
Express News | Amarin Q3 Operating Expenses USD 41.4 Million